Novartis Posts Higher Q3 Profit

Loading...
Loading...
Novartis AG
NVS
reported a rise in its third-quarter profit. The company's net profit attributable to shareholders climbed 44% to $3.22 billion, versus a year-ago profit of $2.23 billion. Its earnings, excluding some items, rose 9% to $3.35 billion, or $1.37 per share, compared to $3.06 billion, or $1.24 per share, in the year-ago period. However, analysts were expecting a profit of $1.29 per share. Its sales rose 4% to $14.7 billion, versus analysts' estimates of $14.34 billion. Pharmaceuticals net sales were USD 7.9 billion, while Alcon net sales rose to USD 2.7 billion. Sandoz net sales climbed to USD 2.4 billion in the quarter. Free cash flow declined 9% to USD 3.2 billion. Its core margin widened by 1.5 percentage points. Joseph Jimenez, CEO of Novartis, said, “Novartis delivered a very strong third quarter. We delivered solid sales growth with margin expansion. At the same time, we reached key innovation milestones, particularly with LCZ696 in heart failure and AIN457 in psoriasis, underlining the innovation power of the company.” Novartis confirmed its forecast for 2014. Novartis shares rose 2.30% to $92.22 in pre-market trading.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsprofit
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...